Matches in SemOpenAlex for { <https://semopenalex.org/work/W28913435> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W28913435 endingPage "33" @default.
- W28913435 startingPage "327" @default.
- W28913435 abstract "The cost-effectiveness of hypolipemiant treatment with lovastatine (0.02, 0.04 and 0.08 g/day), cholestyramine (12 and 24 g/day), cholestipol (10 and 20 g/day) and gemfibrocyl (1.2 g/day) was estimated in individuals presenting hypercholesterolemia (> 200 mg/dl or 5.17 mmol/l) following dietetic treatment.The cost-effectiveness relationship was measured in terms of cost per year of life gained comparing the net cost of the program with its effectiveness for each treatment studied. The net cost of the program was calculated taking the costs associated with hypolipemiant treatment into account and subtracting the estimated reduction of the costs of coronary heart disease attributed to the prevention program. The Framingham equation and the information concerning to the prevalence of cardiovascular risk factors and life expectancy according to age and sex in the Catalonian (Spain) population were used to estimate the effectiveness.The lesser to greater cost per year of life gained is lovastatine-0.02, cholestyramine-12, cholestipol-12, lovastatine-0.04, gemfibrocyl, cholestyramine-24, cholestipol-10, lovastatine-0.08 and cholestipol-20. In males from 45-49 years of age with cholesterol concentration of 300 mg/dl (7.76 mmol/l) the costs per year of life gained were 3.4 millions for lovastatine-0.02, 4.6 for cholestyramine-12, 4.8 for lovastatine-0.04, 5.4 for gemfibrocyl, 6.5 for cholestyramine-24, 7.8 for cholestipol-10, 8.1 for lovastatine 0.08 and 11.6 for cholestipol-20. In women the cost-effectiveness were 11.6, 15.4, 17.7, 21.3, 25.4, 25.9 and 37.1, respectively. The cost-effectiveness for the most effective treatments was less than 5 million of pesetas per year of life gained in males presenting a cholesterol concentration higher than 300 mg/dl (7.76 mmol/l) and those under the age of 65 years. In women the cost-effectiveness was lower than 10 million of pesetas per year of life gained in those presenting more than 340 mg/dl (8.79 mmol/l) under the age of 65 years.The results of this study demonstrate that the administration of lovastatine at 0.02 g/day is the most effective hypolipemiant treatment in preventing coronary heart disease." @default.
- W28913435 created "2016-06-24" @default.
- W28913435 creator A5010425606 @default.
- W28913435 creator A5018791343 @default.
- W28913435 date "1995-09-23" @default.
- W28913435 modified "2023-09-27" @default.
- W28913435 title "[Cost-effectiveness of pharmacologic treatments for the reduction of blood lipids]." @default.
- W28913435 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7500685" @default.
- W28913435 hasPublicationYear "1995" @default.
- W28913435 type Work @default.
- W28913435 sameAs 28913435 @default.
- W28913435 citedByCount "7" @default.
- W28913435 countsByYear W289134352016 @default.
- W28913435 crossrefType "journal-article" @default.
- W28913435 hasAuthorship W28913435A5010425606 @default.
- W28913435 hasAuthorship W28913435A5018791343 @default.
- W28913435 hasConcept C111815664 @default.
- W28913435 hasConcept C112930515 @default.
- W28913435 hasConcept C11783203 @default.
- W28913435 hasConcept C126322002 @default.
- W28913435 hasConcept C133925201 @default.
- W28913435 hasConcept C2778163477 @default.
- W28913435 hasConcept C2778697171 @default.
- W28913435 hasConcept C2779134260 @default.
- W28913435 hasConcept C2908647359 @default.
- W28913435 hasConcept C3019080777 @default.
- W28913435 hasConcept C71924100 @default.
- W28913435 hasConcept C99454951 @default.
- W28913435 hasConceptScore W28913435C111815664 @default.
- W28913435 hasConceptScore W28913435C112930515 @default.
- W28913435 hasConceptScore W28913435C11783203 @default.
- W28913435 hasConceptScore W28913435C126322002 @default.
- W28913435 hasConceptScore W28913435C133925201 @default.
- W28913435 hasConceptScore W28913435C2778163477 @default.
- W28913435 hasConceptScore W28913435C2778697171 @default.
- W28913435 hasConceptScore W28913435C2779134260 @default.
- W28913435 hasConceptScore W28913435C2908647359 @default.
- W28913435 hasConceptScore W28913435C3019080777 @default.
- W28913435 hasConceptScore W28913435C71924100 @default.
- W28913435 hasConceptScore W28913435C99454951 @default.
- W28913435 hasIssue "9" @default.
- W28913435 hasLocation W289134351 @default.
- W28913435 hasOpenAccess W28913435 @default.
- W28913435 hasPrimaryLocation W289134351 @default.
- W28913435 hasRelatedWork W149822611 @default.
- W28913435 hasRelatedWork W1542497037 @default.
- W28913435 hasRelatedWork W1975164269 @default.
- W28913435 hasRelatedWork W2009839413 @default.
- W28913435 hasRelatedWork W2030308479 @default.
- W28913435 hasRelatedWork W2051578861 @default.
- W28913435 hasRelatedWork W2080125917 @default.
- W28913435 hasRelatedWork W2146792483 @default.
- W28913435 hasRelatedWork W2162578173 @default.
- W28913435 hasRelatedWork W28913435 @default.
- W28913435 hasVolume "105" @default.
- W28913435 isParatext "false" @default.
- W28913435 isRetracted "false" @default.
- W28913435 magId "28913435" @default.
- W28913435 workType "article" @default.